Steven Cohen Amylyx Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 170,000 shares of AMLX stock, worth $280,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
170,000
Previous 2,751,305
93.82%
Holding current value
$280,500
Previous $40.5 Million
98.81%
% of portfolio
0.0%
Previous 0.1%
Shares
8 transactions
Others Institutions Holding AMLX
# of Institutions
183Shares Held
50.3MCall Options Held
5.84MPut Options Held
2.06M-
Vanguard Group Inc Valley Forge, PA5.35MShares$8.82 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$7.38 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.94MShares$4.86 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.47MShares$4.08 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.07MShares$3.42 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $96.6M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...